Neurosense Therapeutics Ltd
NRSN0.810USD
-0.008-1.00%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
19.93MMarket Cap
LossP/E TTM
More Details of Neurosense Therapeutics Ltd Company
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Neurosense Therapeutics Ltd Info
Ticker SymbolNRSN
Company nameNeurosense Therapeutics Ltd
IPO dateDec 09, 2021
CEOBen-Noon (Alon)
Number of employees15
Security typeOrdinary Share
Fiscal year-endDec 09
Address11 Hamenofim St.
CityHERZLIYA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code4672562
Phone97297996183
Websitehttps://www.neurosense-tx.com/
Ticker SymbolNRSN
IPO dateDec 09, 2021
CEOBen-Noon (Alon)
Company Executives of Neurosense Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+3.04%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+4.55%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+54.22%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+3.04%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+4.55%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+54.22%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ben-Noon (Alon)
10.69%
Rimon Gold Assets Ltd
7.76%
Eisenberg (Or)
1.62%
Tracik (Ferenc)
0.64%
Squarepoint Capital LLP
0.32%
Other
78.97%
Shareholders
Shareholders
Proportion
Ben-Noon (Alon)
10.69%
Rimon Gold Assets Ltd
7.76%
Eisenberg (Or)
1.62%
Tracik (Ferenc)
0.64%
Squarepoint Capital LLP
0.32%
Other
78.97%
Shareholder Types
Shareholders
Proportion
Individual Investor
13.78%
Corporation
7.76%
Investment Advisor/Hedge Fund
0.37%
Investment Advisor
0.30%
Research Firm
0.15%
Hedge Fund
0.07%
Bank and Trust
0.05%
Other
77.52%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
29
437.13K
1.75%
-1.60M
2025Q2
37
7.64M
31.03%
+143.76K
2025Q1
39
7.45M
37.28%
+353.50K
2024Q4
38
7.90M
34.02%
+1.29M
2024Q3
32
5.18M
22.45%
-1.31M
2024Q2
35
6.62M
30.57%
+1.57M
2024Q1
38
5.18M
33.20%
-953.28K
2023Q4
38
5.12M
32.81%
-1.05M
2023Q3
33
5.76M
47.99%
-945.27K
2023Q2
33
6.46M
53.11%
+1.06M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ben-Noon (Alon)
3.18M
12.68%
+93.67K
+3.04%
Apr 07, 2025
Rimon Gold Assets Ltd
2.30M
9.2%
+2.30M
--
Dec 02, 2024
Eisenberg (Or)
480.92K
1.92%
+20.92K
+4.55%
Apr 07, 2025
Tracik (Ferenc)
189.62K
0.76%
+66.67K
+54.22%
Apr 07, 2025
Squarepoint Capital LLP
49.92K
0.2%
+49.92K
--
Jun 30, 2025
Russek-Blum (Niva)
75.43K
0.3%
+10.00K
+15.28%
Apr 07, 2025
Leuchtenberger (Mark W)
64.00K
0.26%
--
--
Apr 07, 2025
Morgan Stanley & Co. LLC
79.90K
0.32%
+29.40K
+58.21%
Jun 30, 2025
Meitav Investment House Ltd
40.00K
0.16%
--
--
Jun 30, 2025
Binder (Hagit)
32.00K
0.13%
+10.00K
+45.45%
Apr 07, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Neurosense Therapeutics Ltd?
The top five shareholders of Neurosense Therapeutics Ltd are:
Ben-Noon (Alon) holds 3.18M shares, accounting for 12.68% of the total shares.
Rimon Gold Assets Ltd holds 2.30M shares, accounting for 9.20% of the total shares.
Eisenberg (Or) holds 480.92K shares, accounting for 1.92% of the total shares.
Tracik (Ferenc) holds 189.62K shares, accounting for 0.76% of the total shares.
Squarepoint Capital LLP holds 49.92K shares, accounting for 0.20% of the total shares.
Ben-Noon (Alon) holds 3.18M shares, accounting for 12.68% of the total shares.
Rimon Gold Assets Ltd holds 2.30M shares, accounting for 9.20% of the total shares.
Eisenberg (Or) holds 480.92K shares, accounting for 1.92% of the total shares.
Tracik (Ferenc) holds 189.62K shares, accounting for 0.76% of the total shares.
Squarepoint Capital LLP holds 49.92K shares, accounting for 0.20% of the total shares.
What are the top three shareholder types of Neurosense Therapeutics Ltd?
The top three shareholder types of Neurosense Therapeutics Ltd are:
Ben-Noon (Alon)
Rimon Gold Assets Ltd
Eisenberg (Or)
Ben-Noon (Alon)
Rimon Gold Assets Ltd
Eisenberg (Or)
How many institutions hold shares of Neurosense Therapeutics Ltd (NRSN)?
As of 2025Q3, 29 institutions hold shares of Neurosense Therapeutics Ltd, with a combined market value of approximately 437.13K, accounting for 1.75% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -29.29%.
What is the biggest source of revenue for Neurosense Therapeutics Ltd?
In --, the -- business generated the highest revenue for Neurosense Therapeutics Ltd, amounting to -- and accounting for --% of total revenue.
